Indoco Remedies AnaCipher CRO gets clearance on Remote Record Assessment from USFDA
Mumbai: Indoco Remedies has announced that the company's Clinical Research Organisation (CRO), AnaCipher, located in Hyderabad has received clearance on Remote Record Assessment from United States Food and Drug Administration (USFDA).
The Company’s Clinical Research Organisation was inspected by the USFDA in July 2022.
"The USFDA has confirmed that no objectionable conditions were observed during their remote assessment," the company stated in a recent BSE filing.
Commenting on this positive development, Aditi Panandikar, Managing Director, Indoco Remedies Limited, said that “This clearance by USFDA is in continuation to seventh successive FDA inspections which concluded with ZERO 483s for AnaCipher CRO. We are committed to strict adherence to all applicable guidelines and regulations and maintaining the highest quality standards in delivering quality services to our clients.”
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.